CoChat

Treatment Options for Relapsed and Refractory Multiple Myeloma

Open access
Lonial, Sagar, Mitsiades, Constantine S., Richardson, Paul G. · 2011 · Clinical Cancer Research
Cited by 127

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Treatment options for patients with relapsed myeloma have benefited from the development of new targeted agents. The use of bortezomib, thalidomide, and lenalidomide have dramatically changed outcomes for patients with relapsed myeloma. New agents are also in development, on the basis of preclinical rationale, as well as combinations of conventional and novel agents. Together each of these treatment approaches are being tested in phase I, II, and III clinical trials, with the goal of prolonged duration of remission and, ultimately, improved overall survival. Clin Cancer Res; 17(6); 1264–77. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-1805

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 127

Metadata

Authors
Lonial, S., Mitsiades, C. S., & Richardson, P. G.
Venue
Clinical Cancer Research
Published
2011-03-15
Volume
17
Issue
6
Pages
1264-1277
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2169774815
Cited by
127
References
8
FWCI
11.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment Options for Relapsed and Refractory Multiple Myeloma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-1805
The paper
Lonial, S., Mitsiades, C. S., & Richardson, P. G. (2011). Treatment Options for Relapsed and Refractory Multiple Myeloma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-1805

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.